Calgary, Alberta — September 4, 2025 — Leads & Copy — Hemostemix Inc. has launched VesCell.Health in Florida, a website to educate physicians and patients about VesCell™ , its autologous stem cell therapy. Florida law SB 1768 permits VesCell™ use for patients with life-threatening or debilitating conditions who have exhausted standard treatments, under physician order and with informed consent.
The website explains the science of autologous stem cells in plain language and provides access to 11 peer-reviewed publications on VesCell’s safety and efficacy across seven clinical trials. The site offers clear explanations of VesCell, evidence-based results from clinical studies, and localized access for Florida residents.
CEO of Hemostemix, Thomas Smeenk, stated the website’s purpose is to provide patients and families with understandable information backed by science, making VesCell’s benefits clear and approachable. Hemostemix aims to advance the understanding and accessibility of regenerative medicine while adhering to healthcare requirements.
Hemostemix, founded in 2003, is an autologous stem cell therapy company. It has developed and patented VesCell™ (ACP-01). The company has completed seven clinical studies and published results in 11 peer-reviewed publications. ACP-01 is considered a safe and statistically significant treatment for various conditions. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix
